Depo-Provera and Meningioma Litigation
General educational information — not legal advice.
What Is Depo-Provera?
Depo-Provera is a brand name for medroxyprogesterone acetate (MPA), a synthetic progestin hormone used as a long-acting injectable contraceptive. Administered every three months, it has been widely prescribed since its FDA approval in 1992. Millions of women in the United States have used Depo-Provera as a form of birth control.
The Alleged Link to Meningiomas
Meningiomas are tumours that develop in the meninges, the protective membranes surrounding the brain and spinal cord. While most meningiomas are benign, they can cause serious neurological symptoms and may require surgery. Research published in peer-reviewed journals has suggested a statistically significant association between long-term use of high-dose progestins including medroxyprogesterone acetate and an increased risk of intracranial meningiomas.
What the Research Shows
A notable study published in the British Medical Journal (BMJ) in 2024 found that women who used progestins including medroxyprogesterone acetate for extended periods had a substantially elevated risk of developing meningiomas compared to non-users. The risk appeared to increase with duration of use. These findings have prompted significant scientific and legal scrutiny of Depo-Provera safety profile.
Allegations Against the Manufacturer
Lawsuits filed against Pfizer, the manufacturer of Depo-Provera, allege that the company knew or should have known about the risk of meningioma development and failed to adequately warn patients and healthcare providers. Plaintiffs allege that had they been properly informed of this risk, they would have chosen alternative contraceptive methods.
Symptoms of Meningioma
Meningiomas can cause a range of symptoms depending on their size and location, including persistent headaches, vision problems, hearing loss, memory difficulties, seizures, weakness in the limbs, and changes in personality or cognition. Many meningiomas are discovered incidentally during imaging for other conditions. Symptoms may develop gradually over months or years.
Who May Be Affected
Women who used Depo-Provera for an extended period — particularly those who used it for two or more years — and who have subsequently been diagnosed with a meningioma may be among those considering legal action. The litigation is still developing, and eligibility criteria may vary.
The Current State of Litigation
Depo-Provera meningioma litigation is an active and growing area of mass tort law in the United States. Cases have been filed in federal and state courts, and consolidation of federal cases into multidistrict litigation (MDL) has been sought. The litigation is at an early stage, and outcomes remain uncertain.
Important Considerations
This page provides general educational information only. The science regarding Depo-Provera and meningioma risk is still being evaluated, and litigation outcomes are uncertain. Statutes of limitations vary by state and may affect the ability to bring a claim. Anyone who believes they may have been affected should seek independent legal advice from a licensed attorney.
Want to Learn More?
Browse all litigation topics or request general educational information tailored to your situation.